whitepaper
Whitepaper: Profiling oncology candidates
Profiling oncology drug candidates through complementary in vitro assays and in vivo models to better understand their potential clinical applications.
List view / Grid view
Disease Research
whitepaper
Whitepaper: Automated cell culture and screening
This whitepaper describes the automated culturing of hiPSC-derived cells for high-throughput phenotypic screening, using validated phenotypic assays.
news
Flaw found in lab models used to study human blood-brain barrier
Researchers have uncovered a flaw in lab models used to study the human blood-brain barrier and a potential strategy to correct the error.
article
Could downregulating the Drp1 protein prevent Alzheimer’s progression?
In this article, we explore the findings of a study that suggests a newly identified pathway, the Drp1-HK1-NLRP3 signalling axis, could be a promising target for therapies to prevent Alzheimer’s disease progression.
news
Tissue damage and genetic mutations interact to drive pancreatic cancer, finds study
New research shows tissue damage to cells carrying KRAS mutations induces epigenetic changes that promote pancreatic cancer.
news
Study provides insight into muscle wasting in cancer patients
Using a mouse model, researchers found that cancer progression led to fewer skeletal muscle ribosomes, likely explaining muscle wasting.
news
Researchers identify how Zika infects foetuses and a potential drug to prevent it
According to scientists, maternal cells act as a reservoir for Zika, enabling the virus to pass from mother to foetus during pregnancy.
news
Deletions in SARS-CoV-2 Spike protein drive antibody escape, study shows
Researchers have found that SARS-CoV-2 evades immune responses by deleting parts of its genetic sequence that encode for the Spike protein.
news
Could bile acids play a role in Parkinson’s pathogenesis?
A new study suggests bile acids may act as a valuable biomarker for diagnosing and tracking the progression of Parkinson's disease.
news
Majority retain COVID-19 antibodies for six months after infection
A study has shown that 88 percent of people infected by COVID-19 were able to produce SARS-CoV-2 antibodies after six months.
![Dr Jayakrishna Ambati looking into a microscope - macular degeneration research [Credit: UVA Health].](https://www.drugtargetreview.com/wp-content/uploads/Macular-degeneration-Jayakrishna-Ambati-720x500.jpg)
![Dr Jayakrishna Ambati looking into a microscope - macular degeneration research [Credit: UVA Health].](https://www.drugtargetreview.com/wp-content/uploads/Macular-degeneration-Jayakrishna-Ambati.jpg)
news
HIV drugs could be repurposed to prevent the onset of macular degeneration
Analysis reveals people taking nucleoside reverse transcriptase inhibitors are significantly less likely to develop dry macular degeneration, a leading cause of age-related vision loss.
news
Targeting the HCF-1 protein causes cancerous cells to self-destruct
Disrupting the interaction between the MYC oncogene and its co-factor, host cell factor (HCF)–1, was sufficient to cause Burkitt’s lymphoma cells to self-destruct in vivo.
news
N439K variant of SARS-CoV-2 is resistant to some neutralising antibodies, shows study
The N439K mutation improves the interaction between SARS-CoV-2 Spike protein and the viral receptor ACE2 and eludes antibody-mediated immunity, say investigators.
news
UK offers genomics expertise to identify new SARS-CoV-2 variants
The UK Government has said genomics expertise will be offered to countries around the world to identify new variants of SARS-CoV-2.
news
Biomarkers predict Alzheimer’s five years before onset
The discovery of early plasma biomarkers for Alzheimer's disease could transform outcomes by enabling patients to begin treatment early.